RxDoctor Payments Data

Karl Siebert, MD

Glaucoma Specialist · Grand Rapids, MINPI 1205809159

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Alcon accounts for 60.7% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $243, 4.9 times the $50 reported in 2019.

$762in general payments, 2019–2025

Across 25 payments — averaging $30.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$462
  • AbbVie$175
  • Ivantis, Inc$125

What the payments were for

  • Food & beverage$762100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon22$462
AbbVie(2 entities)2$175
Ivantis, Inc1$125

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Michiganto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$243,948
Medicare patients
480
Services billed
1,741

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost261$130,645
CombiganBrimonidine Tartrate/Timolol213$82,926
Latanoprost1,276$24,544
RocklatanNetarsudil Mesylat/Latanoprost40$24,154
RestasisCyclosporine17$22,554
SimbrinzaBrinzolamide/Brimonidine Tart83$21,946
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat724$20,049
Travoprost75$18,820
Timolol Maleate893$18,429
Brimonidine Tartrate240$15,253
Prednisolone Acetate517$15,170
Alphagan PBrimonidine Tartrate36$14,304
Dorzolamide-TimololDorzolamide/Timolol/Pf48$11,382
VyzultaLatanoprostene Bunod20$9,062
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol73$8,716

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$175$250,430527 claims
AlconSimbrinza$462$21,94683 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Michiganon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Grand Rapids

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →